Glutathione Injection Solution

Glutathione Injection Solution

Available presentation(s): 10, 50 mL. Verify the exact concentration and total active quantity on the prescription and dispensing label.

Introduction: Glutathione is an endogenous tripeptide antioxidant. Compounded intravenous use is promoted for several non-standard indications, but robust evidence, validated dosing and long-term safety data are limited.

Dosage: No standard dose is established for general wellness, skin lightening or ‘detoxification’. The 200 mg/mL product must be prescribed in milligrams with route, dilution, infusion rate, frequency, duration and monitoring. Avoid protocol extrapolation from oral or inhaled use.

Mechanisms of Action: Participates in cellular redox buffering, detoxification reactions and maintenance of protein thiol status. Exogenous intravenous pharmacology and translation to clinical outcomes remain incompletely defined.

Contraindications & Precautions: Avoid in hypersensitivity. Use caution in asthma and sulfite sensitivity depending on excipients. Confirm renal/hepatic status and full formulation. Cosmetic skin-lightening use lacks an established favourable benefit-risk profile.

Interactions: Interactions are insufficiently studied. Antioxidant therapy may theoretically affect some chemotherapy or radiotherapy responses; obtain oncology approval. Avoid unvalidated admixtures.

Adverse Reactions / Side Effects: Nausea, abdominal discomfort, headache, flushing, rash, bronchospasm, infusion reactions and rare severe hypersensitivity are possible. Long-term high-dose safety is uncertain.

Pregnancy & Breastfeeding: Insufficient evidence supports compounded intravenous use in pregnancy or breastfeeding. Avoid non-essential treatment.

Storage: Store under the conditions stated on the Optimus dispensing label and product-specific worksheet. Protect from light where labelled. Do not freeze unless explicitly validated. Maintain cold chain if the label requires refrigeration. Do not use after the assigned beyond-use date or if there is visible particulate matter, precipitation, colour change, loss of container integrity or evidence of improper storage. Once entered, follow the validated in-use time; do not assume a compounded vial is multi-dose.

References

• New Zealand Formulary (NZF), current online edition; product-specific approved data sheets where available; USP Pharmaceutical Compounding—Sterile Preparations; and Optimus Healthcare validated formulation, sterility/endotoxin controls and assigned beyond-use date.
• US FDA. Compounding and the FDA: Questions and Answers. Updated 16 September 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers